DarioHealth Statistics
Total Valuation
DarioHealth has a market cap or net worth of $14.90 million. The enterprise value is $16.21 million.
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DarioHealth has 11.29 million shares outstanding. The number of shares has increased by 222.51% in one year.
| Current Share Class | 11.29M |
| Shares Outstanding | 11.29M |
| Shares Change (YoY) | +222.51% |
| Shares Change (QoQ) | +29.08% |
| Owned by Insiders (%) | 20.09% |
| Owned by Institutions (%) | 6.50% |
| Float | 6.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.70 |
| Forward PS | 0.61 |
| PB Ratio | 0.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.20, with a Debt / Equity ratio of 0.46.
| Current Ratio | 4.20 |
| Quick Ratio | 3.74 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.81 |
Financial Efficiency
Return on equity (ROE) is -46.58% and return on invested capital (ROIC) is -18.07%.
| Return on Equity (ROE) | -46.58% |
| Return on Assets (ROA) | -16.51% |
| Return on Invested Capital (ROIC) | -18.07% |
| Return on Capital Employed (ROCE) | -29.44% |
| Weighted Average Cost of Capital (WACC) | 10.82% |
| Revenue Per Employee | $129,103 |
| Profits Per Employee | -$249,263 |
| Employee Count | 165 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, DarioHealth has paid $450,000 in taxes.
| Income Tax | 450,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.57% in the last 52 weeks. The beta is 1.18, so DarioHealth's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -90.57% |
| 50-Day Moving Average | 4.46 |
| 200-Day Moving Average | 7.05 |
| Relative Strength Index (RSI) | 24.07 |
| Average Volume (20 Days) | 73,196 |
Short Selling Information
The latest short interest is 114,624, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 114,624 |
| Short Previous Month | 81,229 |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.75% |
| Short Ratio (days to cover) | 2.06 |
Income Statement
In the last 12 months, DarioHealth had revenue of $21.30 million and -$41.13 million in losses. Loss per share was -$4.28.
| Revenue | 21.30M |
| Gross Profit | 13.06M |
| Operating Income | -30.40M |
| Pretax Income | -33.60M |
| Net Income | -41.13M |
| EBITDA | -28.30M |
| EBIT | -30.40M |
| Loss Per Share | -$4.28 |
Full Income Statement Balance Sheet
The company has $31.15 million in cash and $32.46 million in debt, with a net cash position of -$1.31 million or -$0.12 per share.
| Cash & Cash Equivalents | 31.15M |
| Total Debt | 32.46M |
| Net Cash | -1.31M |
| Net Cash Per Share | -$0.12 |
| Equity (Book Value) | 71.27M |
| Book Value Per Share | 6.36 |
| Working Capital | 29.31M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$23.53 million and capital expenditures -$122,000, giving a free cash flow of -$23.66 million.
| Operating Cash Flow | -23.53M |
| Capital Expenditures | -122,000 |
| Depreciation & Amortization | 2.10M |
| Net Borrowing | n/a |
| Free Cash Flow | -23.66M |
| FCF Per Share | -$2.10 |
Full Cash Flow Statement Margins
Gross margin is 61.30%, with operating and profit margins of -142.69% and -159.86%.
| Gross Margin | 61.30% |
| Operating Margin | -142.69% |
| Pretax Margin | -157.75% |
| Profit Margin | -159.86% |
| EBITDA Margin | -132.84% |
| EBIT Margin | -142.69% |
| FCF Margin | n/a |
Dividends & Yields
DarioHealth does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -222.51% |
| Shareholder Yield | -222.51% |
| Earnings Yield | -324.15% |
| FCF Yield | -158.77% |
Analyst Forecast
The average price target for DarioHealth is $8.00, which is 506.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 506.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 20.17% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 28, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Aug 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
DarioHealth has an Altman Z-Score of -5.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.32 |
| Piotroski F-Score | 1 |